Table 1.
IHC characterisation of intratumoural lymphocytes in MpM variants.
| Case | MpM variants | Intratumoural lymphocytes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumour cells | T cells | NK cells | B cells | Tumour cells | ||||||||
| EZH2 | CD3∗ II | CD8∗ II | CD4 | Tbet | GZMB | Foxp3 | PD1 | CD56 | CD20 | HLA class I§ | ||
| No. 1 | E-MpM | 1 | 3 | 3 | 2 | 2 | 3 | 2 | 0.5 | 0 | 0.5 | Positive |
| No. 2 | E-MpM | 1 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0 | 0 | 0 | 0.5 | Positive |
| No. 3 | E-MpM | 1 | 1 | 1 | 0.5 | 0.5 | 1 | 0.5 | 0 | 0.5 | 0.5 | Positive |
| No. 4 | E-MpM | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 0.5 | 1 | 0.5 | Positive |
| No. 5 | E-MpM | 1 | 1 | 1 | 1 | 0 | 0 | 0.5 | 0 | 0 | 0.5 | Positive |
| No. 6 | E-MpM | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 1 | Positive |
| No. 7 | E-MpM | 1 | 2 | 2 | 2 | 2 | 1.5 | 0.5 | 0.5 | 3 | 0.5 | Positive |
| No. 8 | E-MpM | 1 | 2 | 2 | 1 | 2 | 2 | 1 | 0 | 1 | 0.5 | Positive |
| No. 9 | E-MpM | 1 | 2 | 2 | 0.5 | 1 | 0.5 | 0.5 | 0 | 2 | 0.5 | Positive |
| No. 10 | Pro-E-MpM | 2 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0.5 | Positive |
| No. 11 | Pro-E-MpM | 2 | 2 | 2 | 1 | 0 | 3 | 2 | 0.5 | 3 | 0.5 | Positive |
| No. 12 | HG-E-MpM | 3 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 0 | 1 | 0.5‡ | Negative¶ |
| No. 13 | S-MpM | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0.5 | Negative |
| No. 14 | S-MpM | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Negative |
Note: E-MpM: epithelioid malignant peritoneal mesothelioma; Pro: progressed; HG: high-grade; S: sarcomatoid; GZMB: granzyme B. ∗Scored by the pathologist (S.P.). The scores were assigned semiquantitatively on a 0–3 scale, as follows: 0 = no staining, 0.5 = occasional, 1 = low, 2 = intermediate, and 3 = high. †Automated scoring using Aperio ScanScope. ‡In very small clusters. §HLA class I was evaluated as negative or positive without assigning a semiquantitative score. ¶With the exception of small residual epithelioid cells with tumour foci. IIScores given by the pathologist and Aperio scores correlated significantly; see Supplementary Figure S1.